Inventaire - your friends and communities are your best library

Status of vaccine research and development of vaccines for dengue

author

Anna Durbin

Joachim Hombach

published in: Vaccine

date of publication: 2016-03-10

language: English

main subject: Dengue virus

Cites articles 46

Date

Title

Authors

2015-05-01

A critical assessment of vector control for dengue prevention

Duane J. Gubler, Scott A. Ritchie, Thomas W Scott, Nicole L Achee, T. Alex Perkins, Robert C Reiner
2015

The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus

Simon Iain Hay, Nick Golding, Wim Van Bortel, Guy Hendrickx, Francis Schaffner, David M Pigott, Oliver J. Brady, David L. Smith, Christopher M Barker, Moritz U. G. Kraemer, Janey Messina, Thomas W Scott, Freya M Shearer, Iqbal R F Elyazar, Adrian Q N Mylne, Kirsten A Duda, William Wint, Marianne Sinka
2015-10-09

Recent advances in dengue pathogenesis and clinical management

Cameron P. Simmons, Kirsty McPherson, Jason M. Mackenzie, Bridget Wills, Nguyen Van Vinh Chau
2015-07-27

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

José Luis Arredondo-Garcia, Reynaldo Dietze
2015-09-24

A Candidate Dengue Vaccine Walks a Tightrope

Cameron P. Simmons
2015-12-07

Dengue vaccine: hypotheses to understand CYD-TDV-induced protection
2015-06-11

The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response

Jacky Flipse, Jolanda M Smit
2015-09-27

Dengue human infection models to advance dengue vaccine development

Stephen S Whitehead, Anna Durbin
2015-06-26

The dengue vaccine pipeline: Implications for the future of dengue control

Ira Longini, Betz Halloran, Anna Durbin
2015-03-22

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

Kanta Subbarao, Anna Durbin
2015-03-19

Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial

Dan T Stinchcomb, Jorge E. Osorio, Sharon E Frey, Janae L Stovall
2015-09-15

Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study

Jorge E. Osorio
2015-07-06

Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial

Richard G Jarman, Jeffrey R Currier, Rafael A De La Barrera, Kenneth H Eckels, Monika Simmons, Janine Danko, J Robert Putnak
2015-07-03

Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates
2015-09-27

Next generation dengue vaccines: A review of the preclinical development pipeline

Joachim Hombach
2014-09-14

Dengue

Eva Harris
2014-07-10

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

Dewa Nyoman Wirawan
2014-11-03

Efficacy of a tetravalent dengue vaccine in children in Latin America

José Luis Arredondo-Garcia, Reynaldo Dietze
2014-10-16

Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies

Ananda Nisalak, Richard G Jarman, Butsaya Thaisomboonsuk, Thomas W Scott, Jared Aldstadt, Timothy P Endy, Anon Srikiatkhachorn, Alan L. Rothman, In-Kyu Yoon, Chonticha Klungthong, Stefan Fernandez
2014-09-24

Utility, limitations, and future of non-human primates for dengue research and vaccine development
2014-01-24

Evaluation of dengue virus strains for human challenge studies

Bruce L. Innis
2014-07-23

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study

Dan T Stinchcomb, Jorge E. Osorio, Janae L Stovall
2014-08-01

Construction and preliminary investigation of a novel dengue serotype 4 chimeric virus using Japanese encephalitis vaccine strain SA14-14-2 as the backbone
2013-04-25

The global distribution and burden of dengue

Thomas Jaenisch, John Brownstein, Simon Iain Hay, Oliver J. Brady, Catherine L Moyes, John M. Drake, Peter W. Gething, Cameron P. Simmons, Jeremy Farrar, Samir Bhatt, Anne Gatewood Hoen, Jane P Messina, Osman Sankoh, Thomas W Scott, Dylan B George, Monica F Myers, William Wint, Andrew W Farlow
2013-07-26

Identifying protective dengue vaccines: guide to mastering an empirical process

Scott B Halstead
2013-07-03

Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity

Sourya Shrestha, Aaron A. King, Justin Lessler, Siripen Kalayanarooj, Nicholas G. Reich, Derek Cummings
2013-04-06

Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation

Jeremy Farrar, Peter G. Smith, John Roehrig, Anna Durbin, Joachim Hombach
2013-04-11

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

Daniela Weiskopf, Alessandro Sette, Sujan Shresta, Bjoern Peters, John Sidney, Aravinda M. de Silva, Jason A Greenbaum, Aruna D De Silva, Ravi V Kolla, Anira N Fernando, Anne Broadwater, Benjamin J Doranz
2013-03-05

The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue

Adriana Souza Azevedo, Ricardo Galler
2012-04-12

Dengue

Bridget Wills, Cameron P. Simmons, Jeremy Farrar, Nguyen Van Vinh Chau
2012-03-08

Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil

Alexander Roberto Precioso
2012-11-03

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

Article - wd:Q38773323

Welcome to Inventaire

the library of your friends and communities

learn more